We are live on
!
Find out more
CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.67B
1-Year Est. Return
89%
This Fund
S&P 500
This Quarter
Est. Return
+16%
1 Year Est. Return
+89%
3 Year Est. Return
+264.17%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$324M
AUM Growth
+$28.5M
(+9.6%)
Cap. Flow
-$2.62M
Cap. Flow
% of AUM
-0.81%
Top 10 Holdings %
Top 10 Hldgs %
32.96%
Holding
465
New
18
Increased
159
Reduced
243
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard World Funds Extended Duration ETF
EDV
|
+$3.29M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$1.96M |
| 3 |
Apple
AAPL
|
+$1.92M |
| 4 |
Vaxcyte
PCVX
|
+$1.9M |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.81M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iQIYI
IQ
|
+$5.11M |
| 2 |
Amazon
AMZN
|
+$4.12M |
| 3 |
Airbnb
ABNB
|
+$2.92M |
| 4 |
Analog Devices
ADI
|
+$2.79M |
| 5 |
KE Holdings
BEKE
|
+$2.12M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 41.8% |
| 2 | Consumer Discretionary | 21.38% |
| 3 | Healthcare | 19.26% |
| 4 | Communication Services | 6.74% |
| 5 | Financials | 4.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
351
MaxCyte
MXCT
$136M
| $6.2K | ﹤0.01% |
1,351
-31
| -2% | -$142 |
|
352
Stoke Therapeutics
STOK
$2.13B
| $6.16K | ﹤0.01% |
579
+44
| +8% | +$468 |
|
353
Fate Therapeutics
FATE
$317M
| $6.14K | ﹤0.01% |
1,290
-40
| -3% | -$221 |
|
|
ICPT
354
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $6.05K | ﹤0.01% |
547
-14
| -2% | -$195 |
|
|
AMRN
355
Amarin Corp
AMRN
$297M
| $6K | ﹤0.01% |
252
-7
| -3% | -$180 |
|
356
Enanta Pharmaceuticals
ENTA
$393M
| $5.91K | ﹤0.01% |
276
-7
| -2% | -$206 |
|
|
RPTX
357
DELISTED
Repare Therapeutics
RPTX
| $5.84K | ﹤0.01% |
552
-18
| -3% | -$185 |
|
|
PETQ
358
DELISTED
PetIQ, Inc. Class A Common Stock
PETQ
| $5.79K | ﹤0.01% |
382
-10
| -3% | -$128 |
|
359
Lexicon Pharmaceuticals
LXRX
$1.05B
| $5.69K | ﹤0.01% |
2,485
-72
| -3% | -$191 |
|
360
Cullinan Oncology
CGEM
$1.26B
| $5.55K | ﹤0.01% |
516
-17
| -3% | -$181 |
|
361
Erasca
ERAS
$6.45B
| $5.45K | ﹤0.01% |
1,976
+109
| +6% | +$311 |
|
362
Evolus
EOLS
$536M
| $5.42K | ﹤0.01% |
746
-16
| -2% | -$138 |
|
363
Scholar Rock
SRRK
$6.55B
| $5.37K | ﹤0.01% |
712
+12
| +2% | +$91 |
|
364
Coherus Oncology
CHRS
$181M
| $5.26K | ﹤0.01% |
1,233
+179
| +17% | +$1.06K |
|
365
Ocular Therapeutix
OCUL
$2.25B
| $5.24K | ﹤0.01% |
1,016
-27
| -3% | -$161 |
|
366
MeiraGTx Holdings
MGTX
$1.2B
| $5.24K | ﹤0.01% |
779
+122
| +19% | +$785 |
|
367
Arbutus Biopharma
ABUS
$907M
| $5.01K | ﹤0.01% |
2,177
+57
| +3% | +$148 |
|
368
Vanda Pharmaceuticals
VNDA
$314M
| $4.96K | ﹤0.01% |
753
-16
| -2% | -$103 |
|
|
ALLK
369
DELISTED
Allakos
ALLK
| $4.94K | ﹤0.01% |
1,134
-20
| -2% | -$90 |
|
370
HUTCHMED
HCM
$2.13B
| $4.94K | ﹤0.01% |
412
-43
| -9% | -$587 |
|
371
Texas Roadhouse
TXRH
$14.1B
| $4.94K | ﹤0.01% |
+44
| New | +$4.84K |
|
|
MRSN
372
DELISTED
Mersana Therapeutics
MRSN
| $4.93K | ﹤0.01% |
60
+1
| +2% | +$146 |
|
373
Castle Biosciences
CSTL
$960M
| $4.8K | ﹤0.01% |
350
-10
| -3% | -$203 |
|
|
GBIO
374
DELISTED
Generation Bio
GBIO
| $4.74K | ﹤0.01% |
86
+5
| +6% | +$229 |
|
375
Kodiak Sciences
KOD
$2.72B
| $4.73K | ﹤0.01% |
686
-22
| -3% | -$135 |
|
Similar funds
HA
JPM
CPO
LCI
GWM
JIP
RMC
GACM
China Universal Asset Management Company's Q2 2023 Portfolio in Review
As of Q2 2023, China Universal Asset Management Company held 465 positions worth $324M, up 9.6% from $295M the previous quarter. Its ten largest holdings account for 33% of the portfolio.
China Universal Asset Management Company's Q2 2023 filing shows 18 new, 159 increased, 243 reduced and 13 closed positions. Its largest new stake was Vanguard World Funds Extended Duration ETF: 37,709 shares worth $3.28M. The largest sale was iQIYI, an estimated $5.11M.
By sector, the portfolio is most concentrated in Technology at 42% of assets, up from 38% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- China Universal Asset Management Company's largest Q2 2023 buy was Vanguard World Funds Extended Duration ETF: 37,709 shares worth $3.28M.
- China Universal Asset Management Company added most to Alnylam Pharmaceuticals in Q2 2023, an estimated $1.96M increase.
- China Universal Asset Management Company's biggest Q2 2023 reduction was iQIYI, cutting an estimated $5.11M.
- China Universal Asset Management Company fully exited Block Inc in Q2 2023, selling an estimated $1.35M.
- China Universal Asset Management Company's ten largest holdings make up 33% of its $324M portfolio in Q2 2023.
- China Universal Asset Management Company opened 18 new positions and closed 13 in Q2 2023.
- China Universal Asset Management Company's portfolio value rose 9.6% quarter-over-quarter to $324M.
Based on China Universal Asset Management Company's 13F filing for Q2 2023, filed 28 Jul 2023.